Impax, Teva reach settlement with J&J over ADHD drug

Sept 14 Fri Sep 14, 2012 9:06am EDT

Sept 14 (Reuters) - Impax Laboratories Inc and Israel's Teva Pharmaceutical Industries Ltd settled a two-year patent dispute with Johnson & Johnson, allowing the generic drugmakers to start selling a copy of Johnson & Johnson's ADHD drug from July 14, 2013.

In 2010, J&J unit Alza filed a lawsuit to block Impax from launching a copy of Alza's Concerta extended-release tablets that treat attention deficit hyperactivity disorder.

According to Wolters Kluwer Health, U.S. brand and generic sales of Concerta were about $1.2 billion for the 12 months ended July 2012, Impax said in a statement.

The Concerta products are part of Impax's 2001 strategic alliance agreement with Teva. Teva has already filed with U.S. regulators to get approval for a generic version of the drug.

Under the settlement, Alza has agreed to give Impax and Teva a license to sell generic versions of Concerta on July 14, 2013, or earlier under certain circumstances, Impax said.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.